-transparent.png){kind=logo}
In this double-blind study on 50 depressive patients viloxazine in dosages between 150-300 mg/die, showed to be a very active and well tolerated thymoleptic substance. Its profile of activity seems similar to that of imipramine. The differences in favour of viloxazine were: a more rapid onset of its effect, a more balanced stimulation of energetical level versus clearing up to depressed mood, evident better results in patients aged over 50, fewer drop-outs on account of complications (especially confusional states or psychotic symptom provocations) and fewer side-effects such as vegetative disfunction, vertigo, and weight increase. More initial fatigue reactions, slight sleep disturbances and 3 hypertensive transient reactions must be emphasized on the side of viloxazine.
L Floru, and
G Czarny, and
J Tegeler
July 1979,
Pharmakopsychiatrie, Neuro-Psychopharmakologie,
L Floru, and
G Czarny, and
J Tegeler
April 1982,
Deutsche medizinische Wochenschrift (1946),
L Floru, and
G Czarny, and
J Tegeler
January 1980,
L'Encephale,
L Floru, and
G Czarny, and
J Tegeler
January 1987,
The Turkish journal of pediatrics,
L Floru, and
G Czarny, and
J Tegeler
January 1981,
Psychiatria polska,
L Floru, and
G Czarny, and
J Tegeler
June 1979,
Ceskoslovenska psychiatrie,
L Floru, and
G Czarny, and
J Tegeler
June 1980,
Ceskoslovenska psychiatrie,
L Floru, and
G Czarny, and
J Tegeler
January 1982,
General pharmacology,
L Floru, and
G Czarny, and
J Tegeler
January 1982,
L'Encephale,
L Floru, and
G Czarny, and
J Tegeler
January 1978,
Arzneimittel-Forschung,
